Oral presentation gives more details from the Phase II data where topline results were released on June 29, 2023. Investigators for the Phase II trial concluded that: The majority of the glioma patients displayed uPAR-positive tumors High uPAR expression is significantly correlated with a worse outcome The study demonstrates the potential of uPAR-targeted radionuclide therapy (uTREAT®) for...